Over the past ten quarters, Hologic has beaten consensus earnings estimates in eight instances, delivering an average EPS surprise of 7.8%. The company’s disciplined expense management and recurring revenue streams have helped it sustain this track record. In its most recent report, adjusted EPS exceeded expectations by 9.2%, driven by higher diagnostic instrument utilization and favorable gross margins that expanded by 120 basis points year-over-year. Investors have rewarded the consistency, sending shares up over 35% since the start of last year.

Hologic’s GYN Surgical segment posted a 10.2% revenue increase in the trailing quarter, led by strong adoption of MyoSure tissue removal systems, which grew 15% sequentially. Fluent hysteroscopy procedures rose 12%, while Gynesonics’ Sonata fibroid treatment platform saw a 20% uptick in procedure volumes. Management attributes this momentum to ongoing product enhancements, expanded clinical training initiatives covering over 200 U.S. hospitals, and an uptick in elective outpatient procedures following the easing of scheduling backlogs.

Looking ahead to the upcoming quarter, Hologic enters with two key tailwinds: a robust order backlog in its diagnostics business and continued market penetration in GYN Surgical. The company’s order book stands at $380 million, up 18% year-over-year, reflecting strength in its molecular diagnostics segment. Additionally, operating cash flow has risen 22% over the past twelve months, bolstering the balance sheet and enabling targeted R&D investments. Analysts currently forecast double-digit revenue growth and margin expansion, making another earnings beat a strong possibility.